Riparib 150 mg (Olaparib Tablet) 150mg

Riparib 150 mg tablets contain olaparib, a PARP inhibitor used for cancer therapy. This oral medication is prescribed for certain types of ovarian, breast, pancreatic, and prostate cancers. Store at room temperature and keep out of reach of children. Not intended for self-administration without medical supervision.

Strength

150mg

Pack Size

120s

Storage

Ambient

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Olaparib 150 mg tablets are prescribed for the maintenance treatment of adult patients with advanced ovarian cancer who have responded to platinum-based chemotherapy. It is also used for BRCA-mutated HER2-negative metastatic breast cancer and metastatic pancreatic cancer. The medication helps slow cancer progression by blocking PARP enzymes involved in DNA repair.

Side Effects

Patients may experience mild to moderate side effects such as nausea, fatigue, or digestive discomfort. Some individuals report changes in taste or appetite while taking olaparib. Headaches and dizziness are occasionally noted. These effects vary by individual and should be monitored by a healthcare provider.

Precautions & Warnings

Olaparib should be handled with care to avoid exposure during pregnancy. Use gloves when handling tablets and wash hands thoroughly afterward. Keep the medication in its original packaging and store at room temperature away from moisture and direct sunlight. Do not crush, split, or chew the tablets.

Avoid Interactions

Olaparib may interact with strong CYP3A inhibitors or inducers, affecting its effectiveness. Grapefruit products can alter drug levels in the bloodstream. Caution is advised when combining with other medications metabolized by CYP enzymes. Always inform your healthcare provider about all prescription and over-the-counter drugs being taken.

Frequently Asked Questions

Riparib 150 mg tablets contain olaparib and are used to treat certain advanced cancers, including ovarian, breast, and pancreatic cancers.

Store riparib 150 mg tablets at room temperature in a dry place away from direct light and out of reach of children.

Consult your healthcare provider before combining riparib with other drugs, as it may interact with CYP3A inhibitors or inducers.

Common side effects include nausea, fatigue, digestive issues, and changes in taste or appetite.

Olaparib may cause harm to an unborn baby; avoid handling or taking the medication if pregnant or planning pregnancy.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.